Compare Fidelity National Information Servcs Inc (FIS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Pfizer Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.36 (market cap $17.44B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 9.2× Fidelity National Information Servcs Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Pfizer Inc for 158 Days on average.
| FIS | PFE | |
|---|---|---|
Market Cap | $17.44B | $159.59B |
Volume | 6,437,765 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $68.57 | $29.02 |
52-Week Low | $32.44 | $23.67 |
Typical Hold Time | 88 Days | 158 Days |
Enterprise Value | $37.95B | $211.09B |
Dividend Yield | 5.2% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 2.75% today, with a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. The company shows improving fundamentals with revenue growth from $10.7B in 2025 to projected $12.2B in 2026 and strong profitability metrics including 27.65% net income margin. Recent news highlights strategic wins in core banking modernization and embedded finance platforms.
The stock presents a compelling value opportunity with a low P/E of 5.2 and analyst consensus target of $47.54 (38% upside), though risks include significant debt load and volatile cash flow trends. Institutional sentiment remains positive with 57% buy ratings, but technical weakness near key support at $33 requires monitoring.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
